Asterias Biotherapeutics Inc (AST) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Asterias Biotherapeutics Inc (NYSE:AST) from a buy rating to a hold rating in a research note issued to investors on Tuesday, October 17th.

According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “

Separately, HC Wainwright reaffirmed a buy rating and set a $12.00 price target on shares of Asterias Biotherapeutics in a research report on Monday, October 2nd.

Asterias Biotherapeutics (NYSE:AST) opened at 2.55 on Tuesday. The firm’s 50 day moving average price is $3.16 and its 200 day moving average price is $3.30. Asterias Biotherapeutics has a 12 month low of $2.45 and a 12 month high of $5.80. The stock’s market cap is $127.44 million.

Asterias Biotherapeutics (NYSE:AST) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $1.25 million. Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%. On average, equities research analysts predict that Asterias Biotherapeutics will post ($0.61) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/asterias-biotherapeutics-inc-ast-stock-rating-lowered-by-zacks-investment-research.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Family Management Corp grew its stake in Asterias Biotherapeutics by 15.6% during the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock worth $168,000 after buying an additional 6,416 shares during the period. California State Teachers Retirement System grew its stake in Asterias Biotherapeutics by 4.6% during the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,100 shares during the period. Teachers Advisors LLC grew its stake in Asterias Biotherapeutics by 13.1% during the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock worth $206,000 after buying an additional 6,714 shares during the period. Finally, State Street Corp grew its stake in Asterias Biotherapeutics by 24.1% during the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 63,773 shares during the period.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply